Early diagnosis is critical for positive outcomes in cancer. Although there is no effective cure for cancer, early diagnosis allows physicians to deploy treatments such as surgery, radiation and chemotherapy that can reduce the size of the tumor and increase life expectancy. Research shows that nearly one-half of people who develop cancer are diagnosed late, reducing the chances of successful treatment and limiting their survival chances.
A recent study by postdoctoral researcher Dr. Anna Jansana has revealed that people with type 2 diabetes are more likely to receive late diagnoses if they develop a type of cancer that isn’t screened for routinely.
Jansana is from the International Agency for Research on Cancer’s (IARC) Nutrition and Cancer Multimorbidity Group. During her presentation at the 13th European Breast Cancer Conference, Jansana noted that while bowel and breast cancer screening is publicly available in several countries, other types of cancer such as prostate, lung and ovarian tumors aren’t routinely screened.
As a result, people with type 2 diabetes are more likely to be diagnosed with these types of cancer once they had become advanced and metastasized to other parts of the body.
She said that the study’s results underscored the need to pay close attention to patients who have already been diagnosed with metabolism, heart or blood vessel diseases to ensure cancer symptoms are identified while the disease is still in its infancy. This would increase the chances of treatment succeeding and increase the patient’s life expectancy.
Jansana and her team drew data from the European Prospective Investigation into Cancer and Nutrition (EPIC) study, reviewing 11,945 cancer cases among 400,577 participants. The data set covered cases that had been diagnosed from 1992 to 2012. The researchers found that of the 11,945 participants, 87% did not have a cardiometabolic disease when they received their cancer diagnosis, 5% of the participants had pre-existing cardiovascular disease when they were diagnosed, 7% had type 2 diabetes, and 1% had both type 2 diabetes and cardiovascular disease.
Furthermore, participants who had type 2 diabetes were 26% more likely to be diagnosed with cancer late compared to those who did not have pre-existing cardiometabolic conditions.
Jansana noted that breast and colorectal cancers seemed to be diagnosed before they had metastasized regardless of the presence or absence of type 2 diabetes and cardiovascular disease. Still, she stated that their results indicated that policymakers should consider expanding their health policies and recommendations to cover patients with cardiometabolic diseases during cancer screenings.
Such timely diagnosis can pave the way for medications developed by entities such as QSAM Biosciences Inc. (OTCQB: QSAM) to be used to manage the cancer and increase the survival rates of the affected patients.
NOTE TO INVESTORS: The latest news and updates relating to QSAM Biosciences Inc. (OTCQB: QSAM) are available in the company’s newsroom at https://ibn.fm/QSAM
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
BioMedWire is part of the InvestorBrandNetwork.